A recent article published in the Virology Journal outlined what is currently known about COVID-19 infection and treatments in autoimmune disease patients, including specific diseases which pose a higher risk of infection, disease severity and hospitalization.
Read More »To better characterize the immunopathology of COVID-19, researchers studied the range of autoantibodies triggered by a SARS-CoV-2 infection, as well as infection severity. Generally, the autoantibodies in patients with mild COVID-19 only slightly differed compared to healthy controls. Patients with moderate COVID-19 exhibited more elevated autoantibody counts, whereas those with severe COVID-19 were observed to have the highest levels of autoantibodies.
Read More »“Systemic Lupus Erythematosus (SLE) is uniquely poised at crossroads between the dysregulated immune system and the risk of viral infections, especially in the context of the current COVID-19 pandemic.” Researchers in India studied the impact of common SLE immunosuppressive drugs in SLE patents with COVID-19, as well as risk factors associated with COVID-19 in this patient population.
Read More »Researchers evaluated the characteristics, severity, course of infection, and disease outcomes in COVID-19 patients with and without Systemic Autoimmune Rheumatic Diseases (SARDs). Patients with rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren’s syndrome, Psoriasis, Type 1 Diabetes, Inflammatory Bowel Disease, and Glomerulonephritis, amongst others, were included in the study.
Read More »